Field Medical, a San Diego, CA-based cardiac pulsed field ablation (PFA) technology company, raised $40M in Series A funding.
The round consisted of a $20M in new capital and the conversion of $20M in seed-round debt. Participants included strategics, venture capital firms and family offices, with multiple seed investors reinvesting.
The company intends to use the funds to support the completion of two pilot studies, VCAS for VT and Field PULSE for atrial fibrillation (AF), as well as continued development of its commercial PFA system and operational scale-up in preparation for VERITAS, its pivotal trial focused on VT.
Founded in 2022 and led by Dr. Steven Mickelsen, Field Medical is developing technology for the treatment of all cardiac arrhythmias, including VT and AF. The FieldForce Ablation System, featuring the first built-for-purpose, contact force focal PFA catheter, enables an instantaneous ablation workflow, with therapy delivered in a fraction of a second. Recent results from the VCAS (VT) and PULSE (AF) pilot studies demonstrate the system’s versatility. Empowered by FieldBending, the company’s proprietary technology is positioned as a solution for treating a full spectrum of cardiac arrhythmias.
In 2024, Field Medical’s technology was recognized by the FDA with Breakthrough Device Designation and inclusion in the TAP Pilot Program.
FinSMEs
22/04/2025